1
|
Kim MS, Park CJ, Cho YU, Jang S, Seo EJ, Park CS, Huh J, Im HJ, Seo JJ, Yoon DH, Suh C. JL1 Antigen Expression on Bone Marrow Lymphoma Cells from Patients With Non-Hodgkin Lymphoma. Ann Lab Med 2019; 40:1-6. [PMID: 31432632 PMCID: PMC6713657 DOI: 10.3343/alm.2020.40.1.1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2018] [Revised: 03/16/2019] [Accepted: 07/26/2019] [Indexed: 11/30/2022] Open
Abstract
Background JL1, a CD43 epitope and mucin family cell surface glycoprotein, is expressed on leukemic cells. An anti-JL1 antibody combined with a toxic substance can have targeted therapeutic effects against JL1-positive leukemia; however, JL1 expression on bone marrow (BM) lymphoma cells has not been assessed using flow cytometry. We investigated JL1 expression on BM lymphoma cells from patients with non-Hodgkin lymphoma (NHL) to assess the potential of JL1 as a therapeutic target. Methods Patients with BM involvement of mature B-cell (N=44) or T- and natural killer (NK)-cell (N=4) lymphomas were enrolled from May 2015 to September 2016. JL1 expression on BM lymphoma cells was investigated using flow cytometry. Clinical, pathological, and cytogenetic characteristics, and treatment responses were compared according to JL1 expression status. Results Of the patients with NHL and BM involvement, 37.5% (18/48) were JL1-positive. Among mature B-cell lymphomas, 100%, 38.9%, 33.3%, 100%, and 25.0% of Burkitt lymphomas, diffuse large B-cell leukemias, mantle cell leukemias, Waldenstrom macroglobulinemia, and other B-cell lymphomas, respectively, were JL1-positive. Three mature T- and NK-cell NHLs were JL1-positive. JL1 expression was associated with age (P=0.045), complete response (P=0.004), and BM involvement at follow-up (P=0.017), but not with sex, performance status, the B symptoms, packed marrow pattern, cytogenetic abnormalities, or survival. Conclusions JL1 positivity was associated with superior complete response and less BM involvement in NHL following chemotherapy.
Collapse
Affiliation(s)
- Min Sun Kim
- Department of Laboratory Medicine, Asan Medical Center and University of Ulsan College of Medicine, Seoul, Korea
| | - Chan Jeoung Park
- Department of Laboratory Medicine, Asan Medical Center and University of Ulsan College of Medicine, Seoul, Korea.
| | - Young Uk Cho
- Department of Laboratory Medicine, Asan Medical Center and University of Ulsan College of Medicine, Seoul, Korea
| | - Seongsoo Jang
- Department of Laboratory Medicine, Asan Medical Center and University of Ulsan College of Medicine, Seoul, Korea
| | - Eul Ju Seo
- Department of Laboratory Medicine, Asan Medical Center and University of Ulsan College of Medicine, Seoul, Korea
| | - Chan Sik Park
- Department of Pathology, Asan Medical Center and University of Ulsan College of Medicine, Seoul, Korea
| | - Jooryung Huh
- Department of Pathology, Asan Medical Center and University of Ulsan College of Medicine, Seoul, Korea
| | - Ho Joon Im
- Department of Pediatrics, Asan Medical Center and University of Ulsan College of Medicine, Seoul, Korea
| | - Jong Jin Seo
- Department of Pediatrics, Asan Medical Center and University of Ulsan College of Medicine, Seoul, Korea
| | - Dok Hyun Yoon
- Department of Oncology, Asan Medical Center and University of Ulsan College of Medicine, Seoul, Korea
| | - Cheolwon Suh
- Department of Oncology, Asan Medical Center and University of Ulsan College of Medicine, Seoul, Korea
| |
Collapse
|
2
|
Park SH, You E, Park CJ, Jang S, Cho YU, Yoon CH, Koh KN, Im HJ, Seo JJ. The Incidence and Immunophenotypic and Genetic Features of JL1 Expressing Cells and the Therapeutic Potential of an Anti-JL1 Antibody in De Novo Pediatric Acute Leukemias. Ann Lab Med 2019; 39:358-366. [PMID: 30809981 PMCID: PMC6400720 DOI: 10.3343/alm.2019.39.4.358] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2018] [Revised: 11/01/2018] [Accepted: 01/21/2019] [Indexed: 12/03/2022] Open
Abstract
Background JL1 is a newly identified CD43 epitope that specifically recognizes leukemic cells. We analyzed the incidence of JL1 expression and compared the clinical, immunophenotypic, and genetic characteristics of de novo pediatric acute leukemia patients with respect to JL1 expression status to determine the therapeutic potential of an anti-JL1 antibody. Methods Seventy-eight patients with pediatric acute leukemia (52 with ALL, 26 with AML) diagnosed between December 2014 and January 2016 were enrolled prospectively. Flow cytometry for JL1 expression was performed at diagnosis. Clinical, immunophenotypic, and genetic characteristics were compared with respect to JL1 expression status by the Student t-test/Mann-Whitney U test and chi-square test/Fisher's exact test. Results The incidence of JL1 expression was 76.9% and 84.6% in ALL and AML patients, respectively. ALL patients with JL1 expression showed higher CD10 and cytoplasmic IgM expressions than those without JL1 expression (P=0.022 and 0.003, respectively) and were associated with TCF3-PBX1 and KMT2A-MLLT1 translocations. AML patients with JL1 expression showed higher CD13 and lower CD65 and CD15 expressions than those without JL1 expression (P=0.013, 0.007, and 0.024, respectively) and were associated with RUNX1-RUNX1T1, PML-RARA, and CBFB-MYH11 translocations. The JL1 expression incidence did not differ between ALL and AML, and the JL1 expression status did not affect prognosis. Conclusions Our findings support the potential therapeutic role of anti-JL1 monoclonal antibodies; JL1 expression was associated with specific immunophenotypes and genetic abnormalities. Future studies should examine the prognostic impact of JL1 expression in pediatric acute leukemias.
Collapse
Affiliation(s)
- Sang Hyuk Park
- Department of Laboratory Medicine, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, Korea
| | - Eunkyoung You
- Department of Laboratory Medicine, Inje University College of Medicine, Busan Baik Hospital, Busan, Korea
| | - Chan Jeoung Park
- Department of Laboratory Medicine, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea.
| | - Seongsoo Jang
- Department of Laboratory Medicine, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea
| | - Young Uk Cho
- Department of Laboratory Medicine, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea
| | - Chan Hee Yoon
- Department of Laboratory Medicine, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea
| | - Kyung Nam Koh
- Department of Pediatrics, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea
| | - Ho Joon Im
- Department of Pediatrics, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea
| | - Jong Jin Seo
- Department of Pediatrics, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea
| |
Collapse
|
3
|
Kim S, Hong JW, Cho WD, Moon YR, Yoon SS, Kim MY, Hong KP, Lee YM, Yi JH, Ham YJ, Rah HC, Kim SR, Song HG. Characterization of Two Novel mAbs Recognizing Different Epitopes on CD43. Immune Netw 2014; 14:164-70. [PMID: 24999313 PMCID: PMC4079823 DOI: 10.4110/in.2014.14.3.164] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2014] [Revised: 05/26/2014] [Accepted: 06/01/2014] [Indexed: 12/01/2022] Open
Abstract
JL1, a specific epitope on CD43, is a potential biomarker for the diagnosis of acute leukemia. Although qualitative assays for detecting leukemia-specific CD43 exist, there is a need to develop quantitative assays for the same. Here, we developed two novel monoclonal antibodies (mAbs), 2C8 and 8E10, recognizing different epitopes on CD43. These clones are capable of pairing with YG5, another mAb against JL1 epitope, because they were selectively obtained using sandwich ELISA. Antigens recognized by 2C8 and 8E10 were confirmed as CD43 by western blotting using the CD43-hFC recombinant protein. When expression on various leukemic cell lines was investigated, 2C8 and 8E10 displayed a disparity in the distribution of the epitope. Enzyme assays revealed that these mAbs recognized a sialic acid-dependent epitope on CD43. Using normal thymus and lymph node paraffin-embedded tissues, we confirmed a difference in the epitopes recognized by the two mAbs that was predicted based on the maturity of the cells in the tissue. In summary, we developed and characterized two mAbs, 2C8 and 8E10, which can be used with YG5 in a sandwich ELISA for detecting leukemia-specific CD43.
Collapse
Affiliation(s)
- Soseul Kim
- Department of Pathology, College of Medicine, Chungbuk National University, Cheongju 361-763, Korea. ; Research Institute, DiNonA Inc, Iksan 570-912, Korea
| | | | - Woon-Dong Cho
- Department of Pathology, College of Medicine, Chungbuk National University, Cheongju 361-763, Korea
| | - Yoo Ri Moon
- Department of Pathology, College of Medicine, Chungbuk National University, Cheongju 361-763, Korea. ; Research Institute, DiNonA Inc, Iksan 570-912, Korea
| | | | - Min-Young Kim
- Department of Pathology, College of Medicine, Chungbuk National University, Cheongju 361-763, Korea
| | - Kwon Pyo Hong
- Research Institute, DiNonA Inc, Iksan 570-912, Korea
| | - Yong-Moon Lee
- Department of Pathology, College of Medicine, Chungbuk National University, Cheongju 361-763, Korea
| | | | - Young Jun Ham
- Research Institute, DiNonA Inc, Iksan 570-912, Korea. ; Graduate School of Health Science Convergence, College of Medicine, Chungbuk National University, Cheongju 361-763, Korea
| | - Hyung Chul Rah
- Graduate School of Health Science Convergence, College of Medicine, Chungbuk National University, Cheongju 361-763, Korea
| | - Seung Ryul Kim
- Graduate School of Health Science Convergence, College of Medicine, Chungbuk National University, Cheongju 361-763, Korea
| | - Hyung Geun Song
- Department of Pathology, College of Medicine, Chungbuk National University, Cheongju 361-763, Korea. ; Graduate School of Health Science Convergence, College of Medicine, Chungbuk National University, Cheongju 361-763, Korea
| |
Collapse
|